DCB in contemporary PCI: evidence, technique and physiology-guided decision-making

Sponsored by Medtronic

Anchorperson: F. L. Ribichini

Spokesperson: D. Hildick-Smith

Summary

This EuroPCR 2026 session explores the evolving role of drug-coated balloons (DCB) in contemporary PCI, highlighting how growing clinical evidence, refined procedural strategies and physiology-guided tools are reshaping everyday practice.

The discussion reviews the latest data supporting DCB use, including long-term outcomes from major registries and trials such as SCAAR, Prevail Global and EBC DCB, and examines how these findings translate into real-world decision-making. It also addresses practical considerations in complex PCI, with a focus on emerging indications and technical guidance.

A dedicated segment compares paclitaxel- and sirolimus-coated balloons, exploring their respective roles in current practice. Finally, the integration of CathWorks FFRangio is showcased as a tool to support physiology-guided decision-making in DCB PCI, helping refine lesion assessment and optimise treatment strategy.